Exploring the Role of the BCL-2 Family in Haematopoiesis and Haematopoietic Malignancy

Grant number: 1090500 | Funding period: 2015 - 2019

Completed

Abstract

Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma comprise the majority of blood cancers and are both disease in which the cell death pathway plays a vital role in both the development of the cancer cell and the resistance to chemotherapy. This project aims to examine the mechanisms of cancer in these tumours focussing on lymphoid cancers, and examine the role of new treatments targeting this pathway.

Related publications (2)

Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia

C Sharpe, J Davis, K Mason, C Tam, D Ritchie, R Koldej

2018-12-01

Understanding how cancer and cancer therapies affect the immune system is integral to the rational application of immunotherapies...

Altered B-lymphopoiesis in mice with deregulated thrombopoietin signaling

AE Au, M Lebois, SA Sim, P Cannon, J Corbin, P Gangatirkar, CD Hyland, D Moujalled, A Rutgersson, F Yassinson, BT Kile, KD Mason, AP Ng, WS Alexander, EC Josefsson

2017-12-01

Thrombopoietin (TPO) is the master cytokine regulator of megakaryopoiesis. In addition to regulation of megakaryocyte and platelet..

University of Melbourne Researchers

Kylie Mason